Impacto de la biopsia transrectal de próstata en la función eréctil / The impact of transrectal prostate biopsy on erectile function

Objetivo: Evaluar la función eréctil en distintos periodos de tiempo en pacientes que se someten a biopsia transrectal de próstata. Material y métodos: Trescientos sesenta y cuatro pacientes se sometieron a BTRP. Todos los pacientes se evaluaron utilizando el Índice Internacional de Función Eréctil (IIEF-5); se excluyó a todos los pacientes con resultado positivo para cáncer y con disfunción eréctil o previa en la evaluación inicial. Se incluyó a 93 pacientes, los cuales se evaluaron antes de la biopsia y a las 4, 12 y 24 semanas posteriores a la BTRP, utilizando el IIEF-5 y evaluando la función eréctil a través de estos periodos. Resultados: Se evaluó a 93 pacientes; durante la primera evaluación prebiopsia el 100% presentó ≥ 22 y en la primera evaluación posbiopsia a las 4 semanas el 66,6% tuvo ≥ 22 puntos y el 33.3% presentó disfunción eréctil, identificando una reducción estadísticamente significativa en las puntuaciones del IIEF-5 (p = 0,001). En la segunda evaluación posbiopsia solo el 9,1% de los pacientes persistió con disfunción eréctil, leve y moderada (p = 0,04); al finalizar, el 92,48% de los pacientes tenían ≥ 22 puntos y el 7,52% persistió con disfunción eréctil leve sin presentar una diferencia significativa. (p = 0,1). Conclusiones: Después de la BTRP, la disminución en las puntuaciones de IIEF-5 y la presencia de disfunción eréctil son temporales y transitorias, con una mayor afectación durante el primer mes posterior al procedimiento, mostrando una mejoría a partir del primer mes, y una recuperación casi total a 6 meses

Objective: To assess erectile function at different periods of time in patients who undergo transrectal prostate biopsy (TRPB). Material and methods: A total of 364 patients underwent TRPB. All of the patients were assessed using the International Index of Erectile Function-5 (IIEF-5). All patients with a positive result for cancer or with previous erectile dysfunction in the initial assessment were excluded. Ninety-three patients were included and were assessed before the biopsy and at 4, 12 and 24 weeks after the TRPB, using the IIEF-5 and assessing erectile function across these time periods. Results: We assessed 93 patients. During the first prebiopsy assessment, 100% of the patients scored ≥ 22 points. In the first postbiopsy evaluation at 4 weeks, 66.6% scored ≥ 22 points, and 33.3% had erectile dysfunction, thereby indicating a statistically significant reduction in the IIEF-5 score (P = .001). In the second postbiopsy evaluation, only 9.1% patients still had mild to moderate erectile dysfunction (P = .04). By the end, 92.48% of the patients scored ≥ 22 points, and 7.52% still had mild erectile dysfunction, without presenting a significant difference (P = .1). Conclusions: After a TRPB, the drop in IIEF-5 scores and the presence of erectile dysfunction are temporary and transient, with greater impairment during the first month following the procedure and improvement starting after the first month, with almost total recovery at 6 months

The impact of transrectal prostate biopsy on erectile function. / Impacto de la biopsia transrectal de próstata en la función eréctil.

OBJECTIVE: To assess erectile function at different periods of time in patients who undergo transrectal prostate biopsy (TRPB). MATERIAL AND METHODS: A total of 364 patients underwent TRPB. All of the patients were assessed using the International Index of Erectile Function-5 (IIEF-5). All patients with a positive result for cancer or with previous erectile dysfunction in the initial assessment were excluded. Ninety-three patients were included and were assessed before the biopsy and at 4, 12 and 24 weeks after the TRPB, using the IIEF-5 and assessing erectile function across these time periods. RESULTS: We assessed 93 patients. During the first prebiopsy assessment, 100% of the patients scored ≥22 points. In the first postbiopsy evaluation at 4 weeks, 66.6% scored ≥ 22 points, and 33.3% had erectile dysfunction, thereby indicating a statistically significant reduction in the IIEF-5 score (P=.001). In the second postbiopsy evaluation, only 9.1% patients still had mild to moderate erectile dysfunction (P=.04). By the end, 92.48% of the patients scored ≥ 22 points, and 7.52% still had mild erectile dysfunction, without presenting a significant difference (P=.1). CONCLUSIONS: After a TRPB, the drop in IIEF-5 scores and the presence of erectile dysfunction are temporary and transient, with greater impairment during the first month following the procedure and improvement starting after the first month, with almost total recovery at 6 months.

Terapia de ondas de choque lineales en el tratamiento de la disfunción eréctil / Linear shock wave therapy in the treatment of erectile dysfunction

Introducción: La terapia de ondas de choque lineales (LSWT) es una nueva terapia no invasiva que utiliza ondas de choque de baja intensidad para inducir la angiogénesis local controlada y mejorar significativamente la función eréctil. Objetivo: Evaluar la eficacia de la LSWT en hombres con disfunción eréctil vasculogénica (DE) en un centro de atención de tercer nivel. Material y métodos: Se incluyeron 15 hombres de edades comprendidas entre 45 y 70 años, sexualmente activos con DE vascular leve y moderada, evaluados con el índice internacional de función eréctil (IIEF). El estudio se realizó en 3 etapas: detección, tratamiento y seguimiento. Recibieron 4 sesiones de LSWT semanales (RENOVA®) 5.000 ondas (0,09 mJ/mm2). La función eréctil se evaluó con IIEFF-EF, Perfil del encuentro sexual (SEP) y Cuestionario de evaluación global (GAQ) al mes y a los 6 meses después del tratamiento. Resultados: La tasa de éxito fue del 80% (12/15). Pacientes con DE leve 40% y DE moderada 60%. Se encontró una asociación positiva entre el IIEF-basal (promedio 14,23 pts) y IIEF un mes y 6 meses después del tratamiento (19,69 pts) una diferencia de 5,46 puntos (p < 0,013). Conclusiones: La factibilidad y tolerabilidad de este tratamiento, y sus características potenciales de rehabilitación, hacen que pueda ser una nueva opción terapéutica atractiva para pacientes con DE

Introduction: Linear Shock Wave Therapy (LSWT) is a new noninvasive therapy that uses low-intensity shock waves to induce local angiogenesis promising modality in the treatment of erectile dysfunction (ED). Objective: To evaluate the effectiveness of LSWT in men with vasculogenic erectile dysfunction (ED), in a Tertiary Care Center. Material and methods: Included 15 men aged 45-70 years, sexually active with mild and moderate vascular ED evaluated with the International Index of Erectile Function (IIEF). The study was conducted in three stage: screening, treatment and results. Treatment stage: 4 weekly sessions LSWT (RENOVA ®) 5000 waves (.09 mJ/mm2). Erectile function was assessed with IIEFF-EF, SEP (Sexual Encounter Profile) and GAQ (Global Assessment Questions) at one and six months after treatment. Results: The rate of success was 80% (12/15). Patients with mild ED (6/15) 40% and moderate ED (9/15) 60%. We found a positive association between IIEF-Basal (average 14.23 pts) and IIEF at one month and six months after therapy (19.69 pts) a difference of 5.46 pts. (P < .013). Conclusions: The feasibility and tolerability of this treatment, and rehabilitation potential features, make it this an attractive new treatment option for patients with ED

Linear shock wave therapy in the treatment of erectile dysfunction.

INTRODUCTION: Linear Shock Wave Therapy (LSWT) is a new noninvasive therapy that uses low-intensity shock waves to induce local angiogenesis promising modality in the treatment of erectile dysfunction (ED). OBJECTIVE: To evaluate the effectiveness of LSWT in men with vasculogenic erectile dysfunction (ED), in a Tertiary Care Center. MATERIAL AND METHODS: Included 15 men aged 45-70 years, sexually active with mild and moderate vascular ED evaluated with the International Index of Erectile Function (IIEF). The study was conducted in three stage: screening, treatment and results. Treatment stage: 4 weekly sessions LSWT (RENOVA ®) 5000 waves (.09mJ/mm(2)). Erectile function was assessed with IIEFF-EF, SEP (Sexual Encounter Profile) and GAQ (Global Assessment Questions) at one and six months after treatment. RESULTS: The rate of success was 80% (12/15). Patients with mild ED (6/15) 40% and moderate ED (9/15) 60%. We found a positive association between IIEF-Basal (average 14.23 pts) and IIEF at one month and six months after therapy (19.69 pts) a difference of 5.46 pts. (P<.013). CONCLUSIONS: The feasibility and tolerability of this treatment, and rehabilitation potential features, make it this an attractive new treatment option for patients with ED.